Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Mato

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
British Journal of Haematology|April 25, 2015
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisChristina Howlett, Sonya J Snedecor, Daniel J Landsburg, et al.
Leukemia & Lymphoma|September 20, 2013
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemiaJane Houldsworth, Asha Guttapalli, Venkata Thodima, et al.
BMC Cancer|March 18, 2017
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United StatesChadi Nabhan, Anthony Mato, Christopher R Flowers, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
British Journal of Haematology|May 29, 2015
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myelomaDavid H Vesole, Elizabeth Bilotti, Joshua R Richter, et al.
Cytotherapy|November 3, 2018
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomasNirav N Shah, Sarah J Nagle, Drew A Torigian, et al.
European Journal of Haematology|January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapseRachel Hu, Wei Wei, Agrima Mian, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Cancer Biology & Therapy|August 5, 2009
Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignanciesAnthony Mato, Barry D Fuchs, Daniel F Heitjan, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
British Journal of Haematology|April 25, 2015
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisChristina Howlett, Sonya J Snedecor, Daniel J Landsburg, et al.
Leukemia & Lymphoma|September 20, 2013
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemiaJane Houldsworth, Asha Guttapalli, Venkata Thodima, et al.
BMC Cancer|March 18, 2017
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United StatesChadi Nabhan, Anthony Mato, Christopher R Flowers, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
British Journal of Haematology|May 29, 2015
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myelomaDavid H Vesole, Elizabeth Bilotti, Joshua R Richter, et al.
Cytotherapy|November 3, 2018
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomasNirav N Shah, Sarah J Nagle, Drew A Torigian, et al.
European Journal of Haematology|January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapseRachel Hu, Wei Wei, Agrima Mian, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Cancer Biology & Therapy|August 5, 2009
Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignanciesAnthony Mato, Barry D Fuchs, Daniel F Heitjan, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Pageof 7